Handelsavisen
prelaunch
Companies Healthcare PKP.AX
PK
PKP.AX ASX Pharmaceuticals

Pkp.Ax

A$0,02
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
18,6M AUD
P/E
EV / Rev
Div yield
0,00 %
Op margin
-25,6 %
ROE
1 454,2 %
Net margin
-53,6 %
Debt / equity
-10,65
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

PKP.AX operates in the Pharmaceuticals industry, focusing on Pharmaceuticals & Medical Research, and generates revenue primarily through the development and sale of pharmaceutical products.

Business. PKP.AX operates in the Pharmaceuticals industry, focusing on Pharmaceuticals & Medical Research, and generates revenue primarily through the development and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
1 454,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PKP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PKP.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    PKP.AX operates in the Pharmaceuticals industry, focusing on Pharmaceuticals & Medical Research, and generates revenue primarily through the development and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a negative total equity of -574,000 AUD and a debt-to-equity ratio of -10.65, indicating a highly leveraged position with significant long-term debt of 6,114,000 AUD. Liquidity is constrained, as evidenced by a current ratio of 0.66 and a negative operating cash flow of -8,407,000 AUD, suggesting the company is not generating sufficient cash from operations to meet short-term obligations.

    Profitability is a concern, with a net loss of 8,347,000 AUD and an operating loss of 3,983,000 AUD. The return on equity is 14.54%, which is high in absolute terms but misleading due to the negative equity base. The return on assets is -0.41%, indicating that the company is not generating returns that cover its cost of capital.

    Geographically and segment-wise, the company's exposure is not disclosed in the available data, but the negative net cash position after subtracting total debt suggests a concentration of risk in its core operations.

    Growth trajectory is negative, with a net loss and negative operating and free cash flows. The company's revenue of 15,562,000 AUD is not sufficient to cover its operating costs, and there is no indication of improvement in the near term.

    Risk factors include medium liquidity risk and a negative net cash position after subtracting total debt. The dilution potential is low, but the company's negative equity and high debt levels could lead to further financial stress.

    Recent events include a significant net loss and negative cash flows, which are indicative of operational challenges. No specific recent filings or transcripts are cited in the available data to provide further context.

    Key takeaways
    • The company is highly leveraged with a negative equity position and a debt-to-equity ratio of -10.65.
    • Profitability is a major concern, with a net loss and negative operating income.
    • Liquidity is constrained, as shown by a current ratio of 0.66 and negative operating cash flow.
    • The company's growth trajectory is negative, with no signs of improvement in the near term.
    • Risk factors include medium liquidity risk and a negative net cash position after subtracting total debt.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$0,02
    Market cap
    A$17.4M
    Enterprise value
    A$23.5M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -A$574.0k
    Net cash
    -A$6.1M
    Current ratio
    0.7
    Debt / equity
    -10.7
    ROA
    -40.7%
    ROE
    14.5%
    Cash conversion
    101.0%
    CapEx / revenue
    -6.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-25,6 %Bottom quartile
    Net Margin-53,6 %Bottom quartile
    ROE1 454,2 %Best in class
    Capex / Rev-6,0 %Below median
    D/E-10,65Best in class
    Cash Conv1,01Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • PKP.AX Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PKP.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage